Benzinga | Apr 29, 2021 07:27AM EDT

Lantern Pharma Reports Its Proprietary AI Platform For Precision Oncology Drug Development, RADR, Surpassed 4.6B Datapoints

- The growing A.I. platform, which is expected to reach 10 Billion datapoints in the next 12 months, has been instrumental in uncovering new indications and potential combination regimens leveraging machine learning algorithms for Lantern's pipeline of drug candidates

- The platform has grown 16-fold over the past 12 months, and 4-fold over the past 4 months -- achieving a growth rate of approximately 1 billion data points each month during the first quarter of 2021

- The RADR(r) platform identifies genomically distinct cancer subtypes, provides mechanistic insight about drug-tumor interactions and uncovers patient groups that can respond to specific drugs and compounds that Lantern and its collaborators are developing

DALLAS, April 29, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR(r) artificial intelligence ("A.I.") platform to improve drug discovery and development and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today that RADR(r) has exceeded 4.6 billion datapoints. This 16-fold increase in datapoints overthe past 12 months was also accompanied by other significant improvements in the functionality, feature-set and automation of the drug development platform as well as a significant increase in the number of drugs, drug classes and cancers covered by RADR(r).



"We are extremely pleased to share the fact that we have increased the number of biologically relevant and curated datapoints that power our RADR(r) platform by 16-fold since last May and nearly 4-fold since the beginning of the year. The pace of data acquisition, curation, and tagging achieved during this last campaign is well ahead of schedule and allows us to increasingly focus on building a more complete and more powerful library of algorithms and machine learning models aimed at rapidly answering questions that are fundamental to oncology drug development," stated Panna Sharma, President and CEO of Lantern Pharma. "Our mission to build the world's largest, most robust and most accurate A.I. driven platform for precision oncology drug discovery and development is advancing rapidly. The robustness of the datasets powering RADR(r) is anticipated to continue to improve machine-learning results, accelerate automation of other features and aid oncology drug development for Lantern and our partners with the ultimate focus of benefitting cancer patients."

Lantern is committed to growing and enhancing RADR(r), which it believes is among the largest drug development platforms powered exclusively for oncology drug development and rescue. The growing datapoints, and accompanying functionality in the A.I. platform, allow scientists, biologists, and engineers to collaborate on issues of drug activity, drug response, patient stratification, and cancer biomarkers at a pace which has been unachievable, until now. The developmental focus on increasing the number of datapoints, and improving the performance, power and biological relevance of the algorithms, is expected to yield additional targeted indications for Lantern's current pipeline of drug candidates. We expect that the platform will also help in revealing additional compounds and therapies that can be in-licensed and subsequently developed in a more efficient, and potentially more targeted manner. Lantern has used RADR(r) to uncover indications in multiple cancer sub-types, including CNS (central nervous system) cancers, drug-resistant lung cancers, lung cancer sub-types among never-smokers and SMARCB1 mutated cancers (e.g. Atypical Teratoid Rhabdoid Tumors).

Lantern has filed two additional patent applications directed to the RADR(r) platform that further strengthen the Company's leading position in using A.I. for cancer drug development and drug rescue. The Company's patent applications are directed to using machine learning to predict and discover gene signatures associated with pharmaceutical agents, as well as using automated and machine learning methods on genomic and biomarker data for rescuing, repurposing and repositioning of pharmaceutical agents. Lantern expects to continue developing novel A.I. and machine learning functionality, methods and technologies that it will file patents on both as core technologies and directed in the use of its pipeline of drug candidates.

"As A.I. continues to transform drug development, platforms that can provide a machine-learning, A.I. driven edge are becoming an essential tool for companies to make informed, rapid decisions in cancer indication selection, trial design, validation of mechanisms and potential creation of combination therapy regimens," continued Sharma. "Now, with every major cancer and drug class being covered in our A.I. platform, Lantern can focus not only on accelerating our portfolio, but also on developing collaborations that continue to enhance and validate our platform while delivering insights for our biopharma partners. These RADR(r) powered insights are expected to accelerate development timelines, derisk key decisions and uncover new opportunities that may have gone undeveloped -- ultimately leading to oncology therapies that can increase the personalization of treatment."

"Biopharma companies are looking to launch programs in validated indications more rapidly as they focus on maximizing the potential of each drug candidate," said Mr. Sharma. "We believe that RADR(r) can help design and launch these programs, that continue to grow in complexity, at a fraction of the cost and timeline of traditional oncology drug development. Creating novel genomic and mechanistic insights while also providing specific guidance on designing biomarker driven preclinical studies and clinical trials is an essential component of personalizing cancer treatment. RADR(r) is a powerful platform that can offer a significant competitive advantage for oncology drug development."